Company Novus Therapeutics, Inc. Nasdaq
Equities
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 30/04/20 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 14/03/21 |
Steven N. Perrin
PSD | President | 59 | 13/09/20 |
Eliezer Katz
CTO | Chief Tech/Sci/R&D Officer | - | 22/10/23 |
John Herberger
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/22 |
Bryan E. Smith
CMP | Compliance Officer | 45 | 18/04/21 |
David Hovland
LAW | General Counsel | - | 18/04/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 30/04/17 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 13/09/20 |
John S. McBride
BRD | Director/Board Member | 72 | 30/04/17 |
Steven N. Perrin
PSD | President | 59 | 13/09/20 |
Chief Executive Officer | 51 | 30/04/20 | |
James Robinson
BRD | Director/Board Member | 54 | 30/09/23 |
June Lee
BRD | Director/Board Member | 58 | 08/12/20 |
Jan Hillson
BRD | Director/Board Member | 71 | 01/07/21 |
Allan Kirk
BRD | Director/Board Member | - | 01/10/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 110,086 | 0 | 0 | 61.88 % |
Stock B | 1 | 37,923,614 | 23,466,868 ( 61.88 %) | 0 | |
Stock C | 0 | 4,422 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |